
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES182
An RCT291 found no significant differences between the treatment groups (atorvastatin 10 mg and 80 mg) in the rate of treatment related adverse events (AEs), including myalgia, or persistent elevations in liver enzymes. No incidents of rhabdomyolysis were reported in either treatment group. Level 1++

[@Shepherd_2006]

